Market Research Report
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||383707|
|Published||Content info||227 Pages
Delivery time: 1-2 business days
|Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019|
|Published: November 25, 2019||Content info: 227 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 10, 4, 44, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.